Tympanic Membrane PerforationNCT07893418
Platelet-Rich Fibrin in Revision Cartilage Tympanoplasty
A study testing PRF-supported conchal cartilage tympanoplasty under local anesthesia in people with Tympanic Membrane Perforation and Chronic Otitis Media, run by Bakirkoy Dr. Sadi Konuk Research and Training Hospital at 1 site in Turkey (Türkiye).
Trial summary
The aim of this study is to evaluate the success rate of revision surgery using a conchal cartilage graft supported with autologous platelet-rich fibrin (PRF), performed under local anesthesia, in patients who previously underwent cartilage tympanoplasty and later developed a recurrent perforation of the graft… Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Tympanic Membrane Perforation, Chronic Otitis Media
- What is being tested?
- PRF-supported conchal cartilage tympanoplasty under local anesthesia
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 35 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 15 Feb 2026to 1 Feb 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age between 18 and 65 years Recurrent tympanic membrane perforation after cartilage tympanoplasty performed at our clinic between January 2018 and October 2025 Perforation persisting for at least 3 months Air-bone gap below 30 dB; or air-bone gap above 30 dB with tympanosclerosis noted during the initial surgery, or patient preference for this procedure over open surgery Controlled otorrhea and a dry ear Absence of cholesteatoma and granulation tissue Willingness to participate and signed informed consent
Who cannot join
- Hematological, autoimmune or malignant disease Active middle ear discharge Uncontrolled infection or presence of granulation tissue Clinically or radiologically confirmed cholesteatoma Any condition preventing venous blood sampling for autologous PRF Need for simultaneous ossicular (hearing) reconstruction Age under 18 or over 65 years
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
University of Health Sciences, Bakırköy Dr. Sadi Konuk Training and Research Hospital
Istanbul, Bakırköy, 34147
İbrahim Ömer Gürlek, MD, +905058628939, drogurlek@gmail.com
Burak Kaan İnan, MD
About this study
Official title: An Innovative Approach In Revision Cartilage Tympanoplasty: A Prospective Study With Platelet-Rich Fibrin (PRF) Support
The aim of this study is to evaluate the success rate of revision surgery using a conchal cartilage graft supported with autologous platelet-rich fibrin (PRF), performed under local anesthesia, in patients who previously underwent cartilage tympanoplasty and later developed a recurrent perforation of the graft requiring revision surgery.
In this single-arm prospective study, the perforation will be repaired with a cartilage graft harvested from the concha of the same (previously operated) ear. Both surfaces of the graft will be covered with PRF obtained from the patient's own blood. Patients can be discharged on the same day without systemic antibiotics.
The primary outcome is anatomical success, defined as graft integrity and closure of the perforation. Secondary outcomes include hearing results (air-conduction thresholds and air-bone gap), quality of life (COMQ-12), postoperative pain (VAS), paracetamol use, change in perforation size, complications and operative time. Patients will be followed for 6 months after surgery. A total of 35 patients are planned to be enrolled.
Read the detailed description
Background and Study Design This is a single-center, single-arm prospective study conducted at the Department of Otorhinolaryngology, University of Health Sciences Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey. To identify eligible participants, patients who underwent cartilage tympanoplasty at our clinic between January 2018 and October 2025 will be screened retrospectively. Patients who developed a graft perforation during follow-up and have an indication for revision surgery will be identified, and those meeting the eligibility criteria will be enrolled prospectively. Graft take rates observed during this screening will be reported only as descriptive data on the clinic's general surgical outcomes, without a direct comparative analysis.
Study Procedure Revision surgery will be performed under local anesthesia. Lidocaine hydrochloride with epinephrine, diluted 1:1, will be infiltrated into the external auditory canal and the conchal region. Perforation size will be measured intraoperatively, and a conchal cartilage graft will be harvested from the ipsilateral (previously operated) ear and shaped accordingly. The graft will be supported on both its medial and lateral surfaces with autologous platelet-rich fibrin (PRF), and the perforation will be repaired. Operative time will be recorded in minutes.
PRF Preparation For the preparation of platelet-rich fibrin, 9 mL of venous blood will be collected from each patient into a red-top BD Vacutainer® Clot Activator tube and centrifuged. After centrifugation, the PRF layer formed in the upper part of the tube will be separated and used in the surgical field. The material is fully autologous and contains no additional biomaterials or chemical agents.
Perforation Measurement Perforation size will be measured in two axes (antero-posterior and supero-inferior) in millimeters using a standardized measuring tool. When needed, the estimated area will be calculated assuming an elliptical shape: Area (mm²) = AP diameter × SI diameter × 0.785. Cases with complete graft integrity will be recorded as 0. Postoperative measurements will be taken after cleaning/aspiration of the external auditory canal.
Postoperative Follow-up Patients may be discharged on the same day with oral paracetamol only, without antibiotics. Ear drops containing ciprofloxacin and dexamethasone (5 drops, three times daily) will be used for 2 weeks, from postoperative week 1 to week 3. The COMQ-12 questionnaire will be administered to all patients before surgery.
Postoperative hour 4: pain assessed with VAS Postoperative week 1: VAS pain score, number of paracetamol tablets used, and clinical evaluation for complications Postoperative week 3: graft status assessed after aspiration of the external auditory canal Postoperative months 3 and 6: pure-tone audiometry Postoperative month 6: COMQ-12 repeated to assess change in quality of life
Data Collection Demographic data (age, sex), indication for revision and clinical characteristics of the perforation, operative time, perioperative and postoperative complications, and postoperative analgesic requirement will be recorded for all patients.
Statistical Analysis Analyses will be performed using IBM SPSS Statistics version 26.0. Normality will be assessed with the Shapiro-Wilk test and histograms. Changes over time in air-conduction thresholds, air-bone gap, COMQ-12 scores, VAS scores and perforation area will be analyzed with repeated measures ANOVA or the Friedman test, as appropriate, followed by Bonferroni-corrected or Wilcoxon signed-rank post-hoc comparisons. Changes in binary outcomes such as graft success will be analyzed with the McNemar test. Correlations will be assessed with Pearson or Spearman analysis, and univariate logistic regression may be used to explore factors associated with graft success. A p value < 0.05 will be considered statistically significant.
Sample Size Based on the literature, the sample size was calculated with G*Power (Wilcoxon signed-rank test, one-sample case; effect size d = 0.5, α = 0.05, power = 0.80), yielding a total of 35 patients.
- Being tested
- PRF-supported conchal cartilage tympanoplasty under local anesthesia
- Keywords
- Platelet-Rich Fibrin, Revision Tympanoplasty, Cartilage Tympanoplasty, Conchal Cartilage Graft, Local Anesthesia, Recurrent Tympanic Membrane Perforation
- Medical subject headings
- Tympanic Membrane Perforation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PRF-supported conchal cartilage tympanoplasty under local anesthesiaProcedure or surgery
Also called Platelet-Rich Fibrin (PRF), Revision Cartilage Tympanoplasty
Revision tympanoplasty performed under local anesthesia (lidocaine hydrochloride with epinephrine, diluted 1:1, infiltrated into the external auditory canal and conchal region). Perforation size is measured intraoperatively, and a conchal cartilage graft harvested from the ipsilateral (previously operated) ear is shaped accordingly. The graft is supported on both its medial and lateral surfaces with autologous platelet-rich fibrin obtained by centrifugation of 9 mL of the patient's venous blood, and the perforation is repaired. No additional biomaterials or chemical agents are used.
| Study group | Role | What they receive |
|---|---|---|
| PRF-Supported Conchal Cartilage Tympanoplasty | Experimental | Patients who developed a recurrent tympanic membrane perforation after previous cartilage tympanoplasty will undergo revision surgery under local anesthesia. The perforation will be repaired with a conchal cartilage graft harvested from the same (previously operated) ear and supported on both its medial and lateral surfaces with autologous platelet-rich fibrin (PRF) obtained from the patient's own venous blood. Patients may be discharged on the same day without systemic antibiotics and will be followed for 6 months. Receives: Procedure: PRF-supported conchal cartilage tympanoplasty under local anesthesia |
What is being measured
The primary outcome is the main question the study is designed to answer.
Anatomical Success (Graft Integrity and Closure of Perforation)
Proportion of patients with an intact graft and complete closure of the tympanic membrane perforation, assessed by otomicroscopic examination after aspiration of the external auditory canal. Cases with complete graft integrity will be recorded as successful.
Measured: Postoperative week 3 and postoperative month 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Oct 2026
- Study start15 Feb 2026
- Primary completion1 Feb 2027 (estimated)
- Study completion1 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Tympanic Membrane PerforationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Single-arm prospective study in which all participants undergo revision cartilage tympanoplasty with an autologous platelet-rich fibrin-supported conchal cartilage graft under local anesthesia.
- Masking
- None (open label)
- Enrolment
- 35 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Bakirkoy Dr. Sadi Konuk Research and Training Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, İbrahim Ömer Gürlek, MD, Bakirkoy Dr. Sadi Konuk Research and Training Hospital
- Investigators
- İbrahim Ömer Gürlek, MD, Principal investigator, University of Health Sciences, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Department of Otorhinolaryngology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07893418
- Sponsor's protocol ID
- 2026/21
- Status last verified
- Oct 2026
- First submitted
- 19 Oct 2026
- Last updated
- 26 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Tiple C, Chirila M, Vesa SC, Stamate MC. Plasma-Rich Fibrin-Regenerative Material in Tympanic Membrane Surgery. Medicina (Kaunas). 2023 Jul 13;59(7):1292. doi: 10.3390/medicina59071292.
PubMed 37512103
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Innovative Approach In Revision Cartilage Tympanoplasty: A Prospective Study With Platelet-Rich Fibrin (PRF) Support
- ClinicalTrials.gov ID
- NCT07893418
- Acronym / sponsor ID
- 2026/21
- Keywords
- Platelet-Rich Fibrin, Revision Tympanoplasty, Cartilage Tympanoplasty, Conchal Cartilage Graft, Local Anesthesia, Recurrent Tympanic Membrane Perforation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 35 participants (estimated)
- Lead sponsor
- Bakirkoy Dr. Sadi Konuk Research and Training HospitalOther government
- Study start
- 15 Feb 2026 (actual)
- Primary completion
- 1 Feb 2027 (estimated)
- Study completion
- 1 Feb 2027 (estimated)
- First posted
- 26 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to evaluate the success rate of revision surgery using a conchal cartilage graft supported with autologous platelet-rich fibrin (PRF), performed under local anesthesia, in patients who previously underwent cartilage tympanoplasty and later developed a recurrent perforation of the graft requiring revision surgery.
In this single-arm prospective study, the perforation will be repaired with a cartilage graft harvested from the concha of the same (previously operated) ear. Both surfaces of the graft will be covered with PRF obtained from the patient's own blood. Patients can be discharged on the same day without systemic antibiotics.
The primary outcome is anatomical success, defined as graft integrity and closure of the perforation. Secondary outcomes include hearing results (air-conduction thresholds and air-bone gap), quality of life (COMQ-12), postoperative pain (VAS), paracetamol use, change in perforation size, complications and operative time. Patients will be followed for 6 months after surgery. A total of 35 patients are planned to be enrolled.
Detailed description
Background and Study Design This is a single-center, single-arm prospective study conducted at the Department of Otorhinolaryngology, University of Health Sciences Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey. To identify eligible participants, patients who underwent cartilage tympanoplasty at our clinic between January 2018 and October 2025 will be screened retrospectively. Patients who developed a graft perforation during follow-up and have an indication for revision surgery will be identified, and those meeting the eligibility criteria will be enrolled prospectively. Graft take rates observed during this screening will be reported only as descriptive data on the clinic's general surgical outcomes, without a direct comparative analysis.
Study Procedure Revision surgery will be performed under local anesthesia. Lidocaine hydrochloride with epinephrine, diluted 1:1, will be infiltrated into the external auditory canal and the conchal region. Perforation size will be measured intraoperatively, and a conchal cartilage graft will be harvested from the ipsilateral (previously operated) ear and shaped accordingly. The graft will be supported on both its medial and lateral surfaces with autologous platelet-rich fibrin (PRF), and the perforation will be repaired. Operative time will be recorded in minutes.
PRF Preparation For the preparation of platelet-rich fibrin, 9 mL of venous blood will be collected from each patient into a red-top BD Vacutainer® Clot Activator tube and centrifuged. After centrifugation, the PRF layer formed in the upper part of the tube will be separated and used in the surgical field. The material is fully autologous and contains no additional biomaterials or chemical agents.
Perforation Measurement Perforation size will be measured in two axes (antero-posterior and supero-inferior) in millimeters using a standardized measuring tool. When needed, the estimated area will be calculated assuming an elliptical shape: Area (mm²) = AP diameter × SI diameter × 0.785. Cases with complete graft integrity will be recorded as 0. Postoperative measurements will be taken after cleaning/aspiration of the external auditory canal.
Postoperative Follow-up Patients may be discharged on the same day with oral paracetamol only, without antibiotics. Ear drops containing ciprofloxacin and dexamethasone (5 drops, three times daily) will be used for 2 weeks, from postoperative week 1 to week 3. The COMQ-12 questionnaire will be administered to all patients before surgery.
Postoperative hour 4: pain assessed with VAS Postoperative week 1: VAS pain score, number of paracetamol tablets used, and clinical evaluation for complications Postoperative week 3: graft status assessed after aspiration of the external auditory canal Postoperative months 3 and 6: pure-tone audiometry Postoperative month 6: COMQ-12 repeated to assess change in quality of life
Data Collection Demographic data (age, sex), indication for revision and clinical characteristics of the perforation, operative time, perioperative and postoperative complications, and postoperative analgesic requirement will be recorded for all patients.
Statistical Analysis Analyses will be performed using IBM SPSS Statistics version 26.0. Normality will be assessed with the Shapiro-Wilk test and histograms. Changes over time in air-conduction thresholds, air-bone gap, COMQ-12 scores, VAS scores and perforation area will be analyzed with repeated measures ANOVA or the Friedman test, as appropriate, followed by Bonferroni-corrected or Wilcoxon signed-rank post-hoc comparisons. Changes in binary outcomes such as graft success will be analyzed with the McNemar test. Correlations will be assessed with Pearson or Spearman analysis, and univariate logistic regression may be used to explore factors associated with graft success. A p value < 0.05 will be considered statistically significant.
Sample Size Based on the literature, the sample size was calculated with G*Power (Wilcoxon signed-rank test, one-sample case; effect size d = 0.5, α = 0.05, power = 0.80), yielding a total of 35 patients.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Single-arm prospective study in which all participants undergo revision cartilage tympanoplasty with an autologous platelet-rich fibrin-supported conchal cartilage graft under local anesthesia.
| Arm | Type | Receives |
|---|---|---|
| PRF-Supported Conchal Cartilage Tympanoplasty | Experimental | Procedure: PRF-supported conchal cartilage tympanoplasty under local anesthesiaPatients who developed a recurrent tympanic membrane perforation after previous cartilage tympanoplasty will undergo revision surgery under local anesthesia. The perforation will be repaired with a conchal cartilage graft harvested from the same (previously operated) ear and supported on both its medial and lateral surfaces with autologous platelet-rich fibrin (PRF) obtained from the patient's own venous blood. Patients may be discharged on the same day without systemic antibiotics and will be followed for 6 months. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Age between 18 and 65 years Recurrent tympanic membrane perforation after cartilage tympanoplasty performed at our clinic between January 2018 and October 2025 Perforation persisting for at least 3 months Air-bone gap below 30 dB; or air-bone gap above 30 dB with tympanosclerosis noted during the initial surgery, or patient preference for this procedure over open surgery Controlled otorrhea and a dry ear Absence of cholesteatoma and granulation tissue Willingness to participate and signed informed consent
Key exclusion criteria (1 listed)
- Hematological, autoimmune or malignant disease Active middle ear discharge Uncontrolled infection or presence of granulation tissue Clinically or radiologically confirmed cholesteatoma Any condition preventing venous blood sampling for autologous PRF Need for simultaneous ossicular (hearing) reconstruction Age under 18 or over 65 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PRF-supported conchal cartilage tympanoplasty under local anesthesiaAlso: Platelet-Rich Fibrin (PRF), Revision Cartilage TympanoplastyRevision tympanoplasty performed under local anesthesia (lidocaine hydrochloride with epinephrine, diluted 1:1, infiltrated into the external auditory canal and conchal region). Perforation size is measured intraoperatively, and a conchal cartilage graft harvested from the ipsilateral (previously operated) ear is shaped accordingly. The graft is supported on both its medial and lateral surfaces with autologous platelet-rich fibrin obtained by centrifugation of 9 mL of the patient's venous blood, and the perforation is repaired. No additional biomaterials or chemical agents are used. | Procedure or surgery | PRF-Supported Conchal Cartilage Tympanoplasty |
Primary outcome
Anatomical Success (Graft Integrity and Closure of Perforation)
Time frame: Postoperative week 3 and postoperative month 6
Proportion of patients with an intact graft and complete closure of the tympanic membrane perforation, assessed by otomicroscopic examination after aspiration of the external auditory canal. Cases with complete graft integrity will be recorded as successful.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2026.
- Results publication: PubMed 37512103Tiple C, Chirila M, Vesa SC, Stamate MC. Plasma-Rich Fibrin-Regenerative Material in Tympanic Membrane Surgery. Medicina (Kaunas). 2023 Jul 13;59(7):1292. doi: 10.3390/medicina59071292.
- Individual participant dataSharing planned: No
Related trials for Tympanic Membrane Perforation
Not yet recruiting
Effect of Autologous Serum-Soaked Paper Patch vs. Traditional Dry Paper Patch on Tympanic Membrane Perforations
Tympanic Membrane Perforation
RecruitingObservational study
Bacteriological Evaluation of Children With Otorrhea
Otorrhea
Not yet recruiting
Outcomes of Cartilage Tympanoplasty in Children
Tympanic Membrane Perforation, Conductive Hearing Loss
Not yet recruiting
Does Adding a Fascial Layer to the Cartilage in Tympanoplasty for Large Tympanic Membrane Perforation Affect the Overall Results?
Tympanic Membrane Perforation, Otitis Media
Not yet recruiting
Boomerang-Shaped Cartilage Graft in Endoscopic Tympanoplasty
Tympanic Membrane Perforation, Chronic Otitis Media
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
İbrahim Ömer Gürlek, MD principal investigator
University of Health Sciences, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Department of Otorhinolaryngology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing PRF-supported conchal cartilage tympanoplasty under local anesthesia in people with Tympanic Membrane Perforation and Chronic Otitis Media, run by Bakirkoy Dr. Sadi Konuk Research and Training Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact İbrahim Ömer Gürlek, MD (+905058628939, drogurlek@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Anatomical Success (Graft Integrity and Closure of Perforation) (time frame: Postoperative week 3 and postoperative month 6). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07893418, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026.